Blackstone and TPG Eye $4B-Plus Sale of Hologic Unit

If you've been keeping tabs on big private equity moves, here's one worth watching. Blackstone and TPG — two of the heaviest hitters in the PE world — are reportedly shopping a unit of Hologic, the women's health-focused medical device company, with a price tag north of $4 billion, according to a new report.

For those unfamiliar, Blackstone and TPG are what you'd call classic buyout firms. They raise enormous pools of capital, acquire businesses (or pieces of them), work to grow their value, and then sell for a profit. When two firms of this caliber team up on a deal, it usually signals they see serious upside — or at least a healthy market appetite for whatever they're selling.

Read more Anduril CEO Warns Against IPO During Peak Hype Cycles →

Hologic itself is well known in the healthcare space, particularly for diagnostics and surgical products aimed at women's health. Carving out and selling a division is a common PE playbook move: streamline the portfolio, unlock value, and return capital to investors. A $4 billion-plus target valuation suggests the unit in question is no small side operation.

Deal activity in the healthcare sector has remained resilient even as broader M&A markets have faced headwinds from higher interest rates. A transaction of this size, if it closes, would rank among the more notable healthcare divestitures of the year and could attract interest from strategic buyers — think larger medtech companies — as well as other private equity firms looking for a foothold in the women's health space.

The details are still thin at this stage, so treat this as a deal to monitor rather than a done deal. Continue reading at SeekingAlpha.